1-3 of 3
M.C. Quarre
Close
Sort by
Journal Articles

Prognostic Factors and Response Duration in 419 MDS Treated with Erythropoietin±GCSF: The GFM Experience.

S. Park, C. Kelaidi, S. Grabar, O. Beyne-Rauzy, S. Cheze, V. Bardet, M. Escoffre-Barbe, C. Ravoet, A. Ferrant, N. Vey, H. Dombret, B. Mahe, L. Mannone, L. Legros, L. Aljassem, A. Stamatoullas, D. Vassilief, M.C. Quarre, L. Ades, V. Andrieux, S. Giraudier, S. de Botton, N. Casadevall, P. Fenaux, F. Dreyfus
Journal: Blood
Blood (2006) 108 (11): 522.
https://doi.org/10.1182/blood.V108.11.522.522
Published: 2006
Journal Articles

Low Doses of Thalidomide (Thal) in Low Risk MDS with Transfusion-Dependant Anemia: The GFM THAL-SMD-200 Trial.

J. Tamburini, C. Elie, D. Vassilief, M.C. Quarre, O. Beyne-Rauzy, M. Gardembas, A. Aouba, C. Berthou, L. Sanhes, A. Guerci, A. Stamatoullas, F. Bauduer, J.J. Sotto, L. Legros, S. Vaultier, P. Fenaux, F. Dreyfus, D. Bouscary
Journal: Blood
Blood (2006) 108 (11): 2673.
https://doi.org/10.1182/blood.V108.11.2673.2673
Published: 2006
Journal Articles

High Response Rate to Darbopoetin Alfa in “Low Risk” MDS : Results of a Phase II Study.

L. Mannone, C. Gardin, M.C. Quarre, J.F. Bernard, S. Giraudier, E. Rosenthal, D. Vassilief, F. Hamza, S. Park, J.J. Kiladjian, S. Vaultier, Mo Beyne-Rouzy, S. Cheze, L. Voilliat, P. Agape, F. Dreyfus, P. Fenaux
Journal: Blood
Blood (2004) 104 (11): 69.
https://doi.org/10.1182/blood.V104.11.69.69
Published: 2004